anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Liquid biopsy (LB) has emerged as a highly promising and non-invasive diagnostic approach, particularly in the field of oncology, and has garnered interest in various medical disciplines. This technique involves the examination of biomolecules released into physiological fluids, such as urine samples, blood, and cerebrospinal fluid (CSF). The analysed biomolecules included circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free DNA (cfDNA), exosomes, and other cell-free components. In contrast to conventional tissue biopsies, LB provides minimally invasive diagnostics, offering invaluable insights into tumor characteristics, treatment response, and early disease detection. This Review explores the contemporary landscape of technologies and clinical applications in the realm of LB, with a particular emphasis on the isolation and analysis of ctDNA and/or cfDNA. Various methodologies have been employed, including droplet digital polymerase chain reaction (DDP), BEAMing (beads, emulsion, amplification, and magnetics), TAm-Seq (tagged-amplicon deep sequencing), CAPP-Seq (cancer personalized profiling by deep sequencing), WGBS-Seq (whole genome bisulfite sequencing), WES (whole exome sequencing), and WGS (whole-genome sequencing). Additionally, CTCs have been successfully isolated through biomarker-based cell capture, employing both positive and negative enrichment strategies based on diverse biophysical and other inherent properties. This approach also addresses challenges and limitations associated with liquid biopsy techniques, such as sensitivity, specificity, standardization and interpretability of findings. This review seeks to identify the current technologies used in liquid biopsy samples, emphasizing their significance in identifying tumor markers for cancer detection, prognosis, and treatment outcome monitoring.
Monokines having the immunostimulant activity of Lymphocytes Activating Factor, or Interleukine I (LAF or IL -2), but free from pyrogenicity, are prepared from cell lines capable of liberating cytokines, such as lymphokines or monokines. The cell lines are incubated in primary cultures or in continued lines in an appropriate culture medium in the presence of homologues or derivatives of N-acetyl muramyl-L- alanyl-D-isoglutamine (MDP) that are themselves free from pyrogenicity. The product is recovered from the supernatant layer of the culture medium after the necessary incubation and may then be purified. The pref. cell lines are normal or tumoral granulocytes-macrophagic lines. Suitable homologues of MDP have been described in EP---6068.
Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is:   


Pregabalin is a white or almost white powder with a pKa1 of 4.4 and a pKa2 of 10.1. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (Octanol : Water) is – 1.0.

Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with pregelatinized starch and talc as inactive ingredients. The capsule shells contain gelatin, sodium lauryl sulfate and titanium dioxide. In addition, the orange & red capsule shells contain red iron oxide. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide.
Crossover study with 50 Health care workers using each product with a minimum of 3 days in between. Products will be applied twice as per manufacturer's instructions for a Healthcare Personnel Handwash followed by immediate hand print. Persistent hand prints will be collected after exposure to environmental contaminants in the common areas. Hand prints will also be collected from one hand of 60 patients cared for by a participating Health Care Worker and gloved hand of Health Care Worker. All media contain neutralizers to inactivate active ingredients in each product and on surfaces. Each hand print plate's area of growth will be measured for Colony Forming Units using computerized software.
OBJECTIVE: The objective of this study was to investigate the clinical efficacy and safety of conducting therapeutic drug monitoring (TDM) of vancomycin in patients with postoperative intracerebral haemorrhage.
METHODS: We conducted a retrospective analysis of 435 patients who experienced postoperative cerebral haemorrhage and were treated with vancomycin in the Department of Neurosurgery of Inner Mongolia Autonomous Region People's Hospital from January 2017 to December 2021. Patients were then matched using the propensity score matching method in a ratio of 1:1. Ninety-two pairs of cases were successfully matched, and the data before and after performing vancomycin TDM were analysed.
RESULTS: After PSM, the baseline data of the two groups were balanced. There were no significant differences in the 14-day mortality and length of hospital stay (p>0.05) between the two groups. Compared with the non-TDM group, the TDM group had a higher proportion of patients with normal white blood cells (83.7% vs 56.5%, p=0.000), neutrophil count (57.6% vs 25.0%, p=0.000) and attaining desirable reductions of 80% in procalcitonin (65.2% vs 10.9%, p=0.000) and C-reactive protein (78.3% vs 41.3%, p=0.000) levels. At US$15.82 per additional TDM, TDM significantly promoted patient outcomes, as seen in improvements in the proportion of patients attaining desirable levels of white blood cells, neutrophil count, procalcitonin and C-reactive protein.
CONCLUSIONS: Vancomycin TDM is a safe and effective approach for the treatment of patients with postoperative intracerebral haemorrhage. The empirical use of TDM of vancomycin significantly improved normal values of white blood cells and neutrophil count, achieved desirable reductions of 80% in procalcitonin and C-reactive protein, and reduced nephrotoxicity in patients with postoperative intracerebral haemorrhage.
A medicine reminder device includes a housing, a processing unit, a schedule-setting input unit, a timing unit, light emitting units and medicine containing units. The schedule-setting input unit, the timing unit and the light emitting units are coupled to the processing unit. Each of the medicine containing units corresponds to at least one of the light emitting units, such that at least a part of light, emitted from the light emitting unit, enters the medicine containing unit and then transmits to the outside. The processing unit receives a schedule-setting event through the schedule-setting input unit to obtain timing information. The timing unit receives the timing information and executes a timing event. The processing unit outputs a control signal according to a result resulting from execution of the timing unit, and enables at least one of the light emitting units according to the control signal.
The invention discloses multifunctional acne liquid. Raw materials in a formula of the multifunctional acne liquid include, by weight, 2 parts of chloromycetin, 2 parts of salicylic acid, 0.06 part of chlorpheniramine, 0.1 part of vitamin A, 0.1 part of vitamin C, 0.1 part of vitamin E, 0.3 part of sulphur, 0.2 part of Chinese rhubarb, 2 parts of Chinese angelica root, 2 parts of red-rooted salvia root, 2 parts of wolfberry root, 2 parts of Szechuan lovage rhizome, a proper amount of refined water and 100 parts of anhydrous alcohol. Consumption and physiochemical property of the raw materials are in synergism so as to realize effects of treating acne, improving skin elasticity and resisting allergy. PH value of the multifunctional acne liquid is close to that of human skin, so that the multifunctional acne liquid is non-irritant to skin. After using the multifunctional acne liquid, a person can feel comfortable and soft obviously. The multifunctional acne liquid is free of stabbing pain feel and has obvious effect of treating acne, whitening and resisting allergy.
PURPOSE OF REVIEW: To review findings related to phantom genital sensation, emphasizing phantom sensation in the transgender and gender diverse (TGD) population. We discuss prevalence, presentation and potential implications for sensory outcomes in genital gender-affirming surgery.
RECENT FINDINGS: There is a high prevalence of phantom genital sensations in the TGD population. The prevalence varies by body part, approaching 50% in the most frequently reported transgender phantom - the phantom penis. Unlike genital phantoms that occur after trauma or surgery which are often painful, transgender phantoms are typically neutral and often erogenous in experience. Phantom sensation in the TGD population can be an affirming experience and important part of sexual well being and embodiment.
SUMMARY: Recent studies have begun to characterize the prevalence and presentations of phantom genital sensations in TGD people, informing our evolving understanding of the sensory experiences of the transgender and gender diverse population. Targeting integration of these centrally-mediated phantom genital sensations with the peripherally generated sensation from genital stimulation may represent one potential avenue to improve sensation and embodiment following genital gender-affirming surgical procedures. Additionally, emerging techniques in modern peripheral nerve surgery targeting phantom pain may offer potential treatment options for painful phantom sensation seen after cases of genital surgery or trauma.
Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.
1312232 Preparing 3-methyl-cephalosporanic acid esters GLAXO LABORATORIES Ltd 10 March 1970 [11 March 1969 22 Sept 1969] 12866/69 and 46622/69 Heading C2A 7# - Acylamido - 3 - methyl - cephalosporanic acid esters are prepared by heating a 6#-acylamido-penicillanic acid 1-oxide ester in a reaction-inert organic solvent in the presence of a salt of an amine base of pKb not less than 4 with an acid, which salt may be formed in situ in the reaction mixture. The amine base is preferably an unsaturated heterocyclic tertiary amine, e.g. pyridine, quinoline, iso-quinoline or benzimidazole, which heterocycles may be substituted by C 1 -C 6  alkyl, halogen, acyl, acylamido, cyano, carboxy or aldoximino groups. Another preferred base is aniline or an N-alkyl aniline; the aniline being optionally nuclear-substituted by halogen, alkyl, hydroxy, alkoxy, nitro or carboxy groups. The acid may be an organic sulphonic acid, e.g. hydrocarbyl or pyridyl sulphonic acid; or trifluoracetic acid, or a phosphorus acid, e.g. ortho-, pyro- or poly-phosphoric acid, phosphorous acid or a phosphonic acid. The latter can be aliphatic, araliphatic or aryl phosphonic acids wherein the hydrocarbon moiety may be substituted by halogen, alkyl or nitro groups. When the salt is formed in situ, either the base or the acid may be present in excess of the equivalent amount needed for neutralization or else equivalent proportions of each may be used. The reaction is preferably conducted in one of the solvents used in Specification 1,299,734; the isolation procedures for the product and the procedure used for preparing the penicillin 1- oxide starting material are also similar to the procedures as described in the said Specification.
Tooth cleaning drops with an outer shell defining an inner chamber filled with a tooth cleaning substance. The outer shell may be made of the same material as the tooth cleaning substance. The drops are placed in a user's mouth and punctured to release the tooth cleaning substance held inside and may be used with or without a tooth brush. The apparatus may have a two-part housing defining spaces for forming the drops. The apparatus and drops may be heated or cooled. The drops may be sealed or sprayed. The drops eliminate the need for messy tooth paste tubes and make brushing easier and more convenient.
1,128,170. Pharmaceutical and cosmetic bases. ATLAS CHEMICAL INDUSTRIES, Inc. 23 Sept., 1965 [30 Sept., 1964], No. 40679/65. Heading A5B. [Also in Division B1] A water in oil gel base suitable for the preparation of cosmetic and pharmaceutical products comprises an aqueous solution of sorbitol containing from 5% to 70% by weight of sorbitol and a glycerol partial ester of oleic acid containing at least 35% by weight of monoglyceride. In the Examples, the gel base is used in a cosmetic cream base, a sunscreen cream and lotion, a pigmented makeup base, a sulfur cream, a zinc oxide cream, a calamine cream, a Vitamin A - Vitamin D composition. Anti-histamines, analgesics, cod liver oil and pern balsam are also mentioned.
Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injections with saline. Then the injected areas will be treated with a small amount of UVB.
Purpose: To compare image quality and radiation exposure between super- and ultra-high-resolution helical and super-high-resolution volumetric CT of the temporal bone. Methods: Six cadaveric temporal bone specimens were used to evaluate key temporal bone structures using the following CT reconstruction and acquisition modes: helical and single-volume acquisition modes in super-high resolution (0.25-mm slice thickness, 10242 matrix), and helical mode in ultra-high resolution (0.25-mm slice thickness, 20482 matrix). Two observers performed 5 previously described preoperative measurements, measured noise and signal-to-noise ratios for air, and noise for bone, and rated the visualization of 5 anatomical structures on a 4-point scale, for each reconstruction mode. Radiation dose exposure was recorded for each examination. Results: There was no significant difference between any of the quantitative or qualitative measurements in any of the reconstruction and acquisition modes. There was a slight increase in noise and a decrease in signal-to-noise ratio in the air using the single-volume mode (115 ± 13.1 HU and 8.37 ± 0.91, respectively) compared to the helicoidal super-high-resolution (92.4 ± 11.8 HU and 10.8 ± 1.26, respectively) and helicoidal ultra-high-resolution (91.1 ± 10.7 HU and 10.9 ± 1.39, respectively) modes (P < .002). The volumic CT dose index was 50.9 mGy with helical acquisition and 29.8 mGy with single-volume acquisition mode (P < .0001). Conclusion: The single-volume super-high-resolution acquisition mode allows a reduction in radiation dose exposure without compromising image quality compared to helical scanning, but with a slightly lower signal-to-noise ratio in air with the single-volume mode, while there was no difference in image quality between the helical super- and ultra-high-resolution modes.
The invention relates to a method for preparing general flavone in star-of-Bethlehem and application thereof to antitumor, anti-inflammatory and analgesic medicines, which belongs to the field of medicines. The method overcomes the disadvantage of low proportion of general flavone in components of an extract in the traditional extraction method. The preparation method comprises the following steps of: drying and pulverizing star-of-Bethlehem; carrying out reflux extraction or dipping extraction or percolation extraction by using alcohol or methanol, blending the extracting solutions, and decompressing and concentrating the blended extracting solution; adding water to the concentrated solution, precipitating and centrifuging; separating the centrifugate with macroporous absorbent resin or a polyamide column; eluting with water or diluted ethanol, and eliminating impurities; carrying out gradient elution with ethanol; collecting eluent, decompressing, concentrating, drying and pulverizing to obtain a general flavone extract of star-of-Bethlehem. The invention has the advantages that the effective ingredients of star-of-Bethlehem are screened, the active parts with antitumor, anti-inflammatory and analgesic activity are identified, and the preparation method of general flavone in star-of-Bethlehem is determined. A traditional Chinese medicine preparation, without toxic and side effect and using the general flavone in star-of-Bethlehem as the raw material, is obtained. The invention provides a new selection for antitumor, anti-inflammation and analgesic for clinic.
OBJECTIVE: Recognize the DNA methylation status of the malar melasma and perilesional skin, and its change after treatment with 50 SPF sunscreen (S), 4% niacinamide (N), or 0.025% retinoic acid (RA). METHODS: Fifty-six lesion of 28 female patients without treatment were clinically evaluated, as also the expression of DNA methyl transferases 1 and 3 by real time-PCR (polymerase chain reaction amplification), immunohistochemistry and immunofluorescence. It was initially quantified and after 8 weeks of treatment with S, RA and N. RESULTS: Relative expression of DNA methyl transferases were significantly elevated compared with unaffected skin in all subjects indicating hypermethylation of DNA. Hypermethylation decreased by S (7 vs 3 times relative expression, p\<0.05), RA (7 vs 2 times relative expression p\<0.05), and N (7 vs 1 relative expression p\<0.01) correlated with clinical improvement, this was also supported by immunohistochemistry and immunofluorescence. CONCLUSIONS: The investigators found hypermethylation of DNA in melasma lesions. Environmental factors such as sun radiation may induce DNA hypermethylation triggering hyperpigmentation trough the activation of pathways regulated by epigenetic modifications. Thus, decreasing methylation by sunscreen protection and the genetic transcription modification through N and RA, may allow their clinical improvement regardless its depigmenting effect.
Tumor growth and metastasis require neovascularization, which is dependent on a complex array of factors, such as the production of various pro-angiogenic factors by tumor cells, intercellular signaling, and stromal remodeling. The hypoxic, acidic tumor microenvironment is not only conducive to tumor cell proliferation, but also disrupts the equilibrium of angiogenic factors, leading to vascular heterogeneity, which further promotes tumor development and metastasis. Anti-angiogenic strategies to inhibit tumor angiogenesis has, therefore, become an important focus for anti-tumor therapy. The traditional approach involves the use of anti-angiogenic drugs to inhibit tumor neovascularization by targeting upstream and downstream angiogenesis-related pathways or pro-angiogenic factors, thereby inhibiting tumor growth and metastasis. This review explores the mechanisms involved in tumor angiogenesis and summarizes currently used anti-angiogenic drugs, including monoclonal antibody, and small-molecule inhibitors, as well as the progress and challenges associated with their use in anti-tumor therapy. It also outlines the opportunities and challenges of treating tumors using more advanced anti-angiogenic strategies, such as immunotherapy and nanomaterials.
This project aims to study the mechanisms of brain function by using Human Intracranial Electrophysiology (HIE) methods and is a continuation of the "Localization of Human Brain Function" study done at Dartmouth-Hitchcock Medical Center (DHMC). HIE refers to the recording of brain signals using electrodes which are surgically inserted into the human brain for the clinical purpose of localizing the origins of epileptic seizures.

Secondary to clinical goals, such patients with intracranial EEG electrodes can be safely recruited to participate in research studies, i.e. the research "piggybacks" on procedures that are performed strictly for a clinical purpose. Brain signals obtained using HIE methods during performance of specific tasks have unique properties rich with insight into the inner workings of the human brain. HIE methods can be used together with electrical brain stimulation (EBS) techniques to better understand relationship between brain and behavior. Furthermore, HIE methods can be recorded together with other non-invasive bio-physiological data streams such as pupillometry, electrodermal activity (EDA), cardiac monitoring, and respiratory monitoring to understand the relationship between the brain and many aspects of human physiology.
The purpose of this study was to investigate changes in the lipidome of patients with sepsis to identify signaling lipids associated with poor outcomes that could be linked to future therapies. Adult patients with sepsis were enrolled within 24h of sepsis recognition. Patients meeting Sepsis-3 criteria were enrolled from the emergency department or intensive care unit and blood samples were obtained. Clinical data were collected and outcomes of rapid recovery, chronic critical illness (CCI), or early death were adjudicated by clinicians. Lipidomic analysis was performed on two platforms, the Sciex™ 5500 device to perform a lipidomic screen of 1450 lipid species and a targeted signaling lipid panel using liquid-chromatography tandem mass spectrometry. For the lipidomic screen, there were 274 patients with sepsis: 192 with rapid recovery, 47 with CCI, and 35 with early deaths. CCI and early death patients were grouped together for analysis. Fatty acid (FA) 12:0 was decreased in CCI/early death, whereas FA 17:0 and 20:1 were elevated in CCI/early death, compared to rapid recovery patients. For the signaling lipid panel analysis, there were 262 patients with sepsis: 189 with rapid recovery, 45 with CCI, and 28 with early death. Pro-inflammatory signaling lipids from ω-6 poly-unsaturated fatty acids (PUFAs), including 15-hydroxyeicosatetraenoic (HETE), 12-HETE, and 11-HETE (oxidation products of arachidonic acid [AA]) were elevated in CCI/early death patients compared to rapid recovery. The pro-resolving lipid mediator from ω-3 PUFAs, 14(S)-hydroxy docosahexaenoic acid (14S-HDHA), was also elevated in CCI/early death compared to rapid recovery. Signaling lipids of the AA pathway were elevated in poor-outcome patients with sepsis and may serve as targets for future therapies.
Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
All rectal cancer patients included in the trial will receive short course radiation to the pelvis (with 25 Gy in 5 fractions) followed by chemotherapy with either 6 cycles of 3 weekly CAPOX chemotherapy or 9 cycles of 2 weekly FOLFOX. All colon cancer patients will receive 6 cycles of 3 weekly CAPOX or 9 cycles of 2 weekly FOLFOX. Patients will proceed for SBRT to the metastatic liver +/_ lung lesions and resection of the colorectal primary. Treatment planning is to be done using CT simulation or conventional simulation (Fluorocscopy) as per institutional practice. Simple beam arrangements, such as parallel opposed beams, are favored wherever possible.
Phentermine Hydrochloride Tablet, USP is a sympathomimetic amine anorectic. Its chemical name is α,α,dimethylphenethylamine hydrochloride. The structural formula is as follows:

C10H15N • HCl M.W. 185.7

Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.

Phentermine Hydrochloride Tablets, USP are available as oral tablets containing 37.5 mg of phentermine hydrochloride (equivalent to 30 mg of phentermine base). Each phentermine hydrochloride tablet also contains the following inactive ingredients: corn starch, lactose (anhydrous), magnesium stearate, microcrystalline cellulose, pregelatinized starch, compressible sugar, and FD&C Blue # 1 aluminum lake.